JPMorgan Chase & Co. Has $2.16 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

JPMorgan Chase & Co. lifted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 103.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 85,545 shares of the biopharmaceutical company's stock after purchasing an additional 43,470 shares during the quarter. JPMorgan Chase & Co. owned 0.13% of Celldex Therapeutics worth $2,162,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in CLDX. Vanguard Group Inc. grew its position in shares of Celldex Therapeutics by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company's stock valued at $98,098,000 after acquiring an additional 12,213 shares during the period. American Century Companies Inc. lifted its stake in Celldex Therapeutics by 46.5% in the 4th quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock valued at $15,376,000 after purchasing an additional 193,093 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Celldex Therapeutics by 1.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 544,330 shares of the biopharmaceutical company's stock worth $13,755,000 after purchasing an additional 5,474 shares during the period. Fisher Asset Management LLC increased its position in Celldex Therapeutics by 20.9% during the fourth quarter. Fisher Asset Management LLC now owns 452,497 shares of the biopharmaceutical company's stock worth $11,435,000 after buying an additional 78,145 shares during the last quarter. Finally, Barclays PLC increased its position in Celldex Therapeutics by 140.7% during the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock worth $4,431,000 after buying an additional 76,207 shares during the last quarter.

Celldex Therapeutics Trading Down 2.0 %

Shares of NASDAQ:CLDX traded down $0.43 during trading on Tuesday, reaching $20.93. 708,688 shares of the stock were exchanged, compared to its average volume of 884,195. Celldex Therapeutics, Inc. has a 12 month low of $14.40 and a 12 month high of $47.00. The firm has a market cap of $1.39 billion, a PE ratio of -8.14 and a beta of 1.59. The stock has a 50-day moving average price of $19.14 and a 200-day moving average price of $23.36.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The firm had revenue of $1.18 million during the quarter, compared to analysts' expectations of $1.25 million. On average, sell-side analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CLDX. The Goldman Sachs Group lowered their price target on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. UBS Group began coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $44.00 price target on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Morgan Stanley began coverage on Celldex Therapeutics in a research report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price target on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Friday, February 28th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Celldex Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $55.30.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.